Belfast-based contract research organisation Fusion Antibodies plc (AIM: FAB) announced on Wednesday that it has expanded its collaboration agreement with the US National Cancer Institute (NCI) to include the humanisation of several existing camelid nanobodies developed by NCI.
Camelid nanobodies, derived from camel species, are increasingly valuable in bi-specific therapies and Chimeric Antigen Receptor (CAR) therapies.
This extension builds on the existing partnership where Fusion provides access to its OptiMAL platform for discovering novel antibodies targeting cancer.
NCI, a leading US federal agency for cancer research, collaborates with Fusion to enhance therapeutic antibody development.
Fusion Antibodies specialises in pre-clinical antibody discovery and engineering, serving global pharmaceutical and diagnostic companies.
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024